The role of angiogenesis in melanoma: Clinical treatments and future expectations

The incidence of melanoma has increased rapidly over the past few decades, with mortality accounting for more than 75% of all skin cancers. The high metastatic potential of Melanoma is an essential factor in its high mortality. Vascular angiogenic system has been proved to be crucial for the metastasis of melanoma. An in-depth understanding of angiogenesis will be of great benefit to melanoma treatment and may promote the development of melanoma therapies. This review summarizes the recent advances and challenges of anti-angiogenic agents, including monoclonal antibodies, tyrosine kinase inhibitors, human recombinant Endostatin, and traditional Chinese herbal medicine. We hope to provide a better understanding of the mechanisms, clinical research progress, and future research directions of melanoma.

[1]  J. Łuszczki,et al.  Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines , 2022, International journal of molecular sciences.

[2]  Douglas B. Johnson,et al.  Clinical and genomic correlates of imatinib response in melanomas with KIT alterations , 2022, British Journal of Cancer.

[3]  A. Carneiro,et al.  Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Xiao-lan Li,et al.  Lactate promotes metastasis of normoxic colorectal cancer stem cells through PGC-1α-mediated oxidative phosphorylation , 2022, Cell Death & Disease.

[5]  M. Hung,et al.  Endothelial p130cas confers resistance to anti-angiogenesis therapy , 2022, Cell reports.

[6]  B. Pothuri,et al.  Appropriate Selection of PARP Inhibitors in Ovarian Cancer , 2022, Current Treatment Options in Oncology.

[7]  Shin‐Yup Lee,et al.  Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancer , 2022, Archives of Pharmacal Research.

[8]  Emma S. Hathaway,et al.  Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors , 2022, Journal for ImmunoTherapy of Cancer.

[9]  S. Goerdt,et al.  Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment , 2022, Journal of translational medicine.

[10]  K. Buder-Bakhaya,et al.  Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis , 2022, European Journal of Cancer.

[11]  M. Cheung,et al.  DEPDC1B Promotes Melanoma Angiogenesis and Metastasis through Sequestration of Ubiquitin Ligase CDC16 to Stabilize Secreted SCUBE3 , 2022, Advanced science.

[12]  Yongdong Feng,et al.  Efficacy and safety of recombinant human endostatin during peri-radiotherapy period in advanced non-small-cell lung cancer. , 2022, Future oncology.

[13]  Lingdi Zhao,et al.  Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma , 2020, The oncologist.

[14]  A. Sebestyén,et al.  The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues , 2021, Cancer and Metastasis Reviews.

[15]  Jun Cao,et al.  Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data , 2021, Investigational New Drugs.

[16]  Xiu-qiong Fu,et al.  Inhibition of Src/STAT3 signaling-mediated angiogenesis is involved in the anti-melanoma effects of dioscin. , 2021, Pharmacological research.

[17]  Pengyun Li,et al.  Discovery of highly potent and selective EGFRT790M/L858R TKIs against NSCLC based on molecular dynamic simulation , 2021, European Journal of Medicinal Chemistry.

[18]  P. Caliceti,et al.  Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[19]  S. Carroll,et al.  Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases , 2021, Cells.

[20]  J. Encinar,et al.  ERK5 signalling pathway is a novel target of sorafenib: Implication in EGF biology , 2021, Journal of cellular and molecular medicine.

[21]  P. Lacal,et al.  VEGF-A/VEGFR-1 signalling and chemotherapy-induced neuropathic pain: therapeutic potential of a novel anti-VEGFR-1 monoclonal antibody , 2021, Journal of Experimental & Clinical Cancer Research.

[22]  D. Ribatti,et al.  Nutraceuticals and their role in tumor angiogenesis. , 2021, Experimental cell research.

[23]  J. Borén,et al.  Intussusceptive angiogenesis in human metastatic malignant melanoma. , 2021, The American journal of pathology.

[24]  Xiaosheng Wang,et al.  Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma , 2021, Computational and structural biotechnology journal.

[25]  R. Verdijk,et al.  In Uveal Melanoma, Angiopoietin-2 but Not Angiopoietin-1 Is Increased in High-Risk Tumors, Providing a Potential Druggable Target , 2021, Cancers.

[26]  Nanxin Liu,et al.  Recent advances in, and challenges of, anti-angiogenesis agents for tumor chemotherapy based on vascular normalization. , 2021, Drug discovery today.

[27]  Geunho Choi,et al.  AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer , 2021, Frontiers in Pharmacology.

[28]  M. Guida,et al.  uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells , 2021, Oncology research.

[29]  Jiake Xu,et al.  Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma , 2021, Cell proliferation.

[30]  C. Pereira,et al.  Cell Fate Reprogramming in the Era of Cancer Immunotherapy , 2021, Frontiers in Immunology.

[31]  Chia-Hao Huang,et al.  Analysis of the Internal Hypoxic Environment in Solid Tumor Tissue Using a Folding Paper System. , 2021, ACS applied materials & interfaces.

[32]  M. Ebrahimzadeh,et al.  The role of Hypoxia-Inducible Factor-1alpha and its signaling in melanoma. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[33]  L. Wagner,et al.  Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors , 2021, Cancers.

[34]  Yun Wang,et al.  Advancing to the era of cancer immunotherapy , 2021, Cancer communications.

[35]  C. Dehelean,et al.  An In Vitro-In Vivo Evaluation of the Antiproliferative and Antiangiogenic Effect of Flavone Apigenin against SK-MEL-24 Human Melanoma Cell Line , 2021, Analytical cellular pathology.

[36]  Zhijun Sun,et al.  Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges , 2021, Cancer communications.

[37]  Wei Huang,et al.  Sorafenib derivatives-functionalized gold nanoparticles confer protection against tumor angiogenesis and proliferation via suppression of EGFR and VEGFR-2. , 2021, Experimental cell research.

[38]  Takashi Watanabe Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma , 2021, Cancers.

[39]  B. C. Jena,et al.  Active autophagy in cancer‐associated fibroblasts: Recent advances in understanding the novel mechanism of tumor progression and therapeutic response , 2021, Journal of cellular physiology.

[40]  Qin Zhao,et al.  Vascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  Tongchao Zhang,et al.  Spatiotemporal trends of the global burden of melanoma in 204 countries and territories from 1990 to 2019: Results from the 2019 global burden of disease study , 2021, Neoplasia.

[42]  G. Drăghici,et al.  Assessment of Betulinic Acid Cytotoxicity and Mitochondrial Metabolism Impairment in a Human Melanoma Cell Line , 2021, International journal of molecular sciences.

[43]  J. Rysz,et al.  Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer , 2021, International journal of molecular sciences.

[44]  Haibin Xia,et al.  Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying IL-24/endostatin enhances glioma therapy. , 2021, Cancer letters.

[45]  W. Miller,et al.  Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit , 2021, Molecular Cancer Research.

[46]  Ning Zhang,et al.  Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. , 2021, Journal of integrative medicine.

[47]  M. Zhang,et al.  Tumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms. , 2021, Cancer letters.

[48]  M. Apte,et al.  Angiopoietin inhibitors: A review on targeting tumor angiogenesis. , 2021, European journal of pharmacology.

[49]  D. Del Bufalo,et al.  Bcl-xL: A Focus on Melanoma Pathobiology , 2021, International journal of molecular sciences.

[50]  Douglas B. Johnson,et al.  Defining and Targeting BRAF Mutations in Solid Tumors , 2021, Current Treatment Options in Oncology.

[51]  M. Unno,et al.  The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors , 2021, Medical Oncology.

[52]  Lisong Shen,et al.  Extracellular vesicle‐mediated regulation of tumor angiogenesis— implications for anti‐angiogenesis therapy , 2021, Journal of cellular and molecular medicine.

[53]  Li Zhou,et al.  Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  U. Höpken,et al.  Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth , 2020, Frontiers in Immunology.

[55]  H. Gelderblom,et al.  Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib , 2020, Expert opinion on investigational drugs.

[56]  Suzie Chen,et al.  Overcoming Immune Evasion in Melanoma , 2020, International journal of molecular sciences.

[57]  Y. Bang,et al.  Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial , 2020, Clinical Cancer Research.

[58]  J. Ji,et al.  Sophoridine suppresses lenvatinib‐resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression , 2020, Journal of cellular and molecular medicine.

[59]  M. Moncrieff,et al.  Mitochondrial oxidative phosphorylation in cutaneous melanoma , 2020, British journal of cancer.

[60]  R. Smolarczyk,et al.  Invited submission by the editor marek los vascular disrupting agents in cancer therapy. , 2020, European journal of pharmacology.

[61]  Fenghua Wang,et al.  Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study , 2020, Investigational New Drugs.

[62]  F. Amant,et al.  Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[63]  T. Rodrigues,et al.  Therapeutic potential of targeting mitochondrial dynamics in cancer. , 2020, Biochemical pharmacology.

[64]  Ken Kato,et al.  Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503) , 2020, ESMO Open.

[65]  J. Nova,et al.  Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population , 2020, BioMed research international.

[66]  Desong Yang,et al.  Parthenolide Inhibits Angiogenesis in Esophageal Squamous Cell Carcinoma Through Suppression of VEGF , 2020, OncoTargets and therapy.

[67]  P. Rutkowski,et al.  Targeted Therapy in Melanoma and Mechanisms of Resistance , 2020, International journal of molecular sciences.

[68]  L. Filippi,et al.  Current Therapies and New Targets to Fight Melanoma: A Promising Role for the β3-Adrenoreceptor , 2020, Cancers.

[69]  Suping Li,et al.  Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells , 2020, Acta Pharmacologica Sinica.

[70]  Xiaoling Zhang,et al.  Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling , 2020, Cancer biology & medicine.

[71]  E. Licărete,et al.  Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment , 2020, International journal of molecular sciences.

[72]  Yiyan Lei,et al.  HIF-1ɑ-regulated miR-1275 maintains stem cell-like phenotypes and promotes the progression of LUAD by simultaneously activating Wnt/β-catenin and Notch signaling , 2020, Theranostics.

[73]  R. Motzer,et al.  Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  G. Lenz,et al.  Lymphoma angiogenesis is orchestrated by noncanonical signaling pathways. , 2020, Cancer research.

[75]  Anubhab Mukherjee,et al.  Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer , 2020, International journal of molecular sciences.

[76]  W. Ciszewski,et al.  Endothelial Cells in the Tumor Microenvironment. , 2020, Advances in experimental medicine and biology.

[77]  M. Aghi,et al.  Autophagy as a Mechanism for Anti-Angiogenic Therapy Resistance. , 2020, Seminars in cancer biology.

[78]  A. Reynolds,et al.  Vessel co-option and resistance to anti-angiogenic therapy , 2019, Angiogenesis.

[79]  M. Barbaccia,et al.  Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib , 2019, Journal of cellular and molecular medicine.

[80]  M. Mita,et al.  PARP Inhibition in Cancer: An Update on Clinical Development , 2019, Targeted Oncology.

[81]  A. Carrato,et al.  Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms , 2019, International journal of molecular sciences.

[82]  Xiaoming Wang,et al.  Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway. , 2019, European journal of pharmacology.

[83]  H. Hollema,et al.  Serotonin and Dopamine Receptor Expression in Solid Tumours Including Rare Cancers , 2019, Pathology & Oncology Research.

[84]  K. Flaherty,et al.  Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Xuri Li,et al.  Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets. , 2019, Pharmacological research.

[86]  M. R. Ruocco,et al.  Metabolic flexibility in melanoma: a potential therapeutic target. , 2019, Seminars in cancer biology.

[87]  G. Jour,et al.  Role of angiogenesis in melanoma progression: update on key angiogenic mechanisms and other associated components. , 2019, Seminars in cancer biology.

[88]  P. Delrio,et al.  Lenvatinib, a molecule with versatile application: from preclinical evidence to future development in anti-cancer treatment , 2019, Cancer management and research.

[89]  M. Caligiuri,et al.  Adipocytes: A Novel Target for IL-15/IL-15Rα Cancer Gene Therapy. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  M. Weinstock,et al.  Cutaneous nevi and risk of melanoma death in women and men: A prospective study , 2019, Journal of the American Academy of Dermatology.

[91]  Yunjian Zhang,et al.  ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway , 2019, Journal of experimental & clinical cancer research : CR.

[92]  I. Zupkó,et al.  A Comprehensive Assessment of Apigenin as an Antiproliferative, Proapoptotic, Antiangiogenic and Immunomodulatory Phytocompound , 2019, Nutrients.

[93]  M. Haris,et al.  Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance , 2019, Molecular Cancer.

[94]  H. Moch,et al.  Eight autopsy cases of melanoma brain metastases showing angiotropism and pericytic mimicry. Implications for extravascular migratory metastasis , 2019, Journal of cutaneous pathology.

[95]  E. Thiele,et al.  Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis , 2019, Orphanet Journal of Rare Diseases.

[96]  S. Aamdal,et al.  Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma , 2019, Clinical and experimental immunology.

[97]  A. M. Troncoso,et al.  Inhibition of VEGFR-2 Phosphorylation and Effects on Downstream Signaling Pathways in Cultivated Human Endothelial Cells by Stilbenes from Vitis Spp. , 2019, Journal of Agricultural and Food Chemistry.

[98]  Anping Li,et al.  Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy , 2019, Journal of Hematology & Oncology.

[99]  M. Zeman,et al.  Synergic effects of inhibition of glycolysis and multikinase receptor signalling on proliferation and migration of endothelial cells. , 2019, General physiology and biophysics.

[100]  R. Raman,et al.  Anti-angiogenic effect of adiponectin in human primary microvascular and macrovascular endothelial cells. , 2019, Microvascular research.

[101]  H. Pan,et al.  Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: a systematic review and meta-analysis of clinical randomized phase III trials , 2019, Journal of Cancer.

[102]  B. Baradaran,et al.  Dimethyl fumarate: Regulatory effects on the immune system in the treatment of multiple sclerosis , 2018, Journal of cellular physiology.

[103]  L. Farahmand,et al.  Challenges facing antiangiogenesis therapy: The significant role of hypoxia‐inducible factor and MET in development of resistance to anti‐vascular endothelial growth factor‐targeted therapies , 2018, Journal of cellular physiology.

[104]  E. White,et al.  Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). , 2019, Cancer treatment and research communications.

[105]  J. Johansson,et al.  Consumption of whole grain/bran rye instead of refined wheat decrease concentrations of TNF-R2, e-selectin, and endostatin in an exploratory study in men with prostate cancer. , 2019, Clinical nutrition.

[106]  Yan Wu,et al.  Cryptotanshinone inhibits the growth and invasion of colon cancer by suppressing inflammation and tumor angiogenesis through modulating MMP/TIMP system, PI3K/Akt/mTOR signaling and HIF‐1&agr; nuclear translocation , 2018, International immunopharmacology.

[107]  I. Tempera,et al.  Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1 , 2018, PLoS pathogens.

[108]  L. A. Al Kury,et al.  Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[109]  J. Kirkwood,et al.  NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma , 2018, Cancer.

[110]  T. Dragovich,et al.  Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma , 2018, OncoTargets and therapy.

[111]  P. Lacal,et al.  Therapeutic implication of vascular endothelial growth factor receptor‐1 (VEGFR‐1) targeting in cancer cells and tumor microenvironment by competitive and non‐competitive inhibitors , 2018, Pharmacological research.

[112]  N. Li,et al.  Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer Cells , 2018, Journal of Cancer.

[113]  E. Brambilla,et al.  VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop , 2018, Oncogene.

[114]  Juke Zheng,et al.  Induction of the mitochondrial NDUFA4L2 protein by HIF-1a regulates heart regeneration by promoting the survival of cardiac stem cell. , 2018, Biochemical and biophysical research communications.

[115]  F. Zhou,et al.  Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study. , 2018, European journal of cancer.

[116]  V. Servois,et al.  Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases , 2018, The journal of pathology. Clinical research.

[117]  P. Lorigan,et al.  25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial , 2018, British Journal of Cancer.

[118]  P. Dziewulski,et al.  Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  D. Teti,et al.  Genistein reduces proliferation of EP3‐expressing melanoma cells through inhibition of PGE2‐induced IL‐8 expression , 2018, International immunopharmacology.

[120]  K. Osann,et al.  Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma , 2018, Cancer Chemotherapy and Pharmacology.

[121]  R. Sullivan,et al.  Management of Metastatic Melanoma in 2018 , 2018, JAMA oncology.

[122]  Y. Huan,et al.  A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (CBCRT01) , 2018, International journal of cancer.

[123]  R. Pearson,et al.  Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance , 2018, International journal of cancer.

[124]  Yibo Tang,et al.  Endostatin gene therapy delivered by attenuated Salmonellatyphimurium in murine tumor models , 2018, Cancer Gene Therapy.

[125]  Paolo A Ascierto,et al.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.

[126]  F. Howe,et al.  Assessment of the direct effects of DDAH I on tumour angiogenesis in vivo , 2018, Angiogenesis.

[127]  Peijun Liu,et al.  Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF‐1α‐induced pro‐angiogenic factor , 2018, Cancer science.

[128]  R. Giavazzi,et al.  Anti-angiogenesis for cancer: Current status and prospects. , 2018, Thrombosis research.

[129]  Li-ping Yang,et al.  A vaccine targeting basic fibroblast growth factor elicits a protective immune response against murine melanoma , 2018, Cancer biology & therapy.

[130]  G. Balistreri,et al.  Lymphatic endothelium stimulates melanoma metastasis and invasion via MMP14-dependent Notch3 and β1-integrin activation , 2018, eLife.

[131]  W. Sperl,et al.  Melanoma tumors exhibit a variable but distinct metabolic signature , 2018, Experimental dermatology.

[132]  J. Steinbach,et al.  Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma , 2018, Journal of neurochemistry.

[133]  Yu-Ying He,et al.  Mechanisms and prevention of UV‐induced melanoma , 2018, Photodermatology, photoimmunology & photomedicine.

[134]  Zheng Liu,et al.  Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway , 2017, Oncology letters.

[135]  A. Tiwari,et al.  MicroRNA Key to Angiogenesis Regulation: MiRNA Biology and Therapy. , 2017, Current cancer drug targets.

[136]  J. Lawler,et al.  Integration of pro- and anti-angiogenic signals by endothelial cells , 2018, Journal of Cell Communication and Signaling.

[137]  D. Schadendorf,et al.  A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma , 2018, Investigational New Drugs.

[138]  R. Milner,et al.  Chronic mild hypoxia promotes profound vascular remodeling in spinal cord blood vessels, preferentially in white matter, via an α5β1 integrin-mediated mechanism , 2018, Angiogenesis.

[139]  J. Ledermann,et al.  Front-line therapy of advanced ovarian cancer: new approaches , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[140]  A. Laurenzana,et al.  uPA/uPAR system activation drives a glycolytic phenotype in melanoma cells , 2017, International journal of cancer.

[141]  Shan Wang,et al.  Endostatin sensitizes p53‐deficient non‐small‐cell lung cancer to genotoxic chemotherapy by targeting DNA‐dependent protein kinase catalytic subunit , 2017, The Journal of pathology.

[142]  T. Petrova,et al.  Microenvironmental regulation of tumour angiogenesis , 2017, Nature Reviews Cancer.

[143]  B. Larrivée,et al.  Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.

[144]  Bruno Larrivée,et al.  Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.

[145]  Santoshi Muppala,et al.  Thrombospondin-4 mediates TGF-β-induced angiogenesis , 2017, Oncogene.

[146]  R. Dummer,et al.  Developments in targeted therapy in melanoma. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[147]  R. Dummer,et al.  The safety of anti PD-1 therapeutics for the treatment of melanoma , 2017, Expert opinion on drug safety.

[148]  C. Balch,et al.  The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[149]  O. Casanovas,et al.  Angiogenesis and Metabolism: Entwined for Therapy Resistance. , 2017, Trends in cancer.

[150]  A. Andiappan,et al.  Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice , 2016, Scientific Reports.

[151]  R. Dummer,et al.  An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel , 2016, The British journal of dermatology.

[152]  Qingshun Zhao,et al.  Cryptotanshinone, a novel tumor angiogenesis inhibitor, destabilizes tumor necrosis factor‐α mRNA via decreasing nuclear–cytoplasmic translocation of RNA‐binding protein HuR , 2016, Molecular carcinogenesis.

[153]  E. Smyth,et al.  Immunotherapy for Gastroesophageal Cancer , 2016, Journal of clinical medicine.

[154]  V. Servois,et al.  Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study , 2016, British Journal of Cancer.

[155]  J. Carles,et al.  Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients , 2016, Cell reports.

[156]  Lixia Xu,et al.  Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib. , 2016, Cancer letters.

[157]  H. Kleinman,et al.  Imaging of Angiotropism/Vascular Co-Option in a Murine Model of Brain Melanoma: Implications for Melanoma Progression along Extravascular Pathways , 2016, Scientific Reports.

[158]  G. Christofori,et al.  VEGF receptor-2-specific signaling mediated by VEGF-E induces hemangioma-like lesions in normal and in malignant tissue , 2016, Angiogenesis.

[159]  F. Roviello,et al.  Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. , 2016, Cancer letters.

[160]  G. Jour,et al.  Angiogenesis in melanoma: an update with a focus on current targeted therapies , 2016, Journal of Clinical Pathology.

[161]  A. D. Van den Abbeele,et al.  Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma , 2015, Cancer.

[162]  S. Katiyar,et al.  Silymarin inhibits melanoma cell growth both in vitro and in vivo by targeting cell cycle regulators, angiogenic biomarkers and induction of apoptosis , 2015, Molecular carcinogenesis.

[163]  F. Hodi,et al.  Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data , 2015, Front. Oncol..

[164]  T. Salo,et al.  Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment. , 2015, Experimental cell research.

[165]  J. Nemunaitis,et al.  Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma , 2015, Clinical Cancer Research.

[166]  J. Tímár,et al.  Mechanism of tumour vascularization in experimental lung metastases , 2015, The Journal of pathology.

[167]  B. Dréno,et al.  Comparative analysis of BRAF, NRAS and c‐KIT mutation status between tumor tissues and autologous tumor cell‐lines of stage III/IV melanoma , 2015, Experimental dermatology.

[168]  S. Carmichael,et al.  Angiotropism, Pericytic Mimicry and Extravascular Migratory Metastasis in Melanoma: An Alternative to Intravascular Cancer Dissemination , 2014, Cancer Microenvironment.

[169]  J. Wolchok,et al.  A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma. , 2014, European journal of cancer.

[170]  D. Neri,et al.  Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy , 2014, Cancer Immunology, Immunotherapy.

[171]  Cizhong Jiang,et al.  Tumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression. , 2014, Cancer letters.

[172]  A. D. Van den Abbeele,et al.  Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma , 2014, Cancer Immunology Research.

[173]  A. Sood,et al.  Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches , 2014, Cancer and Metastasis Reviews.

[174]  Masao Iwata,et al.  Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. , 2013, Cancer letters.

[175]  Ping Yang,et al.  Jatrorrhizine hydrochloride inhibits the proliferation and neovascularization of C8161 metastatic melanoma cells , 2013, Anti-cancer drugs.

[176]  T. Kume,et al.  FoxC1-dependent regulation of vascular endothelial growth factor signaling in corneal avascularity. , 2013, Trends in cardiovascular medicine.

[177]  S. Okolicsanyi,et al.  Cyclic AMP/PKA‐dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin‐2 defective mice treated with sorafenib , 2012, Hepatology.

[178]  M. Mukherji,et al.  Honokiol inhibits HIF pathway and hypoxia-induced expression of histone lysine demethylases. , 2012, Biochemical and biophysical research communications.

[179]  S. Puig,et al.  Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway , 2012, International journal of cancer.

[180]  M. Shibuya Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. , 2011, Genes & cancer.

[181]  Y. Okada,et al.  Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production , 2011, British Journal of Cancer.

[182]  Yang Zhang,et al.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[183]  Jeeyun Lee,et al.  Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia , 2011, Melanoma research.

[184]  A. Suttle,et al.  An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors , 2010, Clinical pharmacology and therapeutics.

[185]  Daniel B. Neill,et al.  Honokiol Inhibits Epidermal Growth Factor Receptor Signaling and Enhances the Antitumor Effects of Epidermal Growth Factor Receptor Inhibitors , 2010, Clinical Cancer Research.

[186]  Rakesh K. Singh,et al.  CXCL8 and its cognate receptors in melanoma progression and metastasis. , 2010, Future oncology.

[187]  J. Gallo,et al.  Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. , 2009, Neuro-oncology.

[188]  J. Kirkwood,et al.  Management of metastatic melanoma. , 2007, Seminars in oncology.

[189]  C. Leonetti,et al.  Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. , 2007, European journal of cancer.

[190]  D. Pinkel,et al.  Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[191]  Qinghua Zhou,et al.  [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. , 2005, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[192]  A. Figueras,et al.  Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. , 2004, The Journal of investigative dermatology.

[193]  L. Akslen,et al.  Angiogenesis is prognostically important in vertical growth phase melanomas. , 1999, International journal of oncology.

[194]  Leonard,et al.  Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. , 1997, Cancer research.

[195]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[196]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[197]  T. Fears,et al.  Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the United States. , 1977, American journal of epidemiology.

[198]  P. Shubik,et al.  The growth of the blood supply to melanoma transplants in the hamster cheek pouch. , 1966, Laboratory investigation; a journal of technical methods and pathology.

[199]  Michael Schwenk,et al.  Tumor , 1828, The London medical and physical journal.